- Home
- BTTC vs ATRA Comparison
BTTC vs ATRA Comparison
Compare BTTC & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$1.60
HOLD
Current Price
$4.49
Company Overview
Basic Information| Metric | BTTC | ATRA |
|---|---|---|
| Founded | 1990 | 2012 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.5M | 37.6M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | BTTC | ATRA |
|---|---|---|
| Price | $1.60 | $4.49 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 3.8M | 220.5K |
| Earning Date | 01-01-0001 | 03-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | 0.72 | ★ 1.97 |
| Revenue | $2,719,480.00 | ★ $151,930,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.39 | ★ $2.26 |
| Revenue Growth | 2.04 | ★ 51.27 |
| 52 Week Low | $1.51 | $4.20 |
| 52 Week High | $39.00 | $19.15 |
Technical Indicators
Market Signals| Indicator | BTTC | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 38.31 | 29.45 |
| Support Level | $1.68 | $4.37 |
| Resistance Level | $1.77 | $5.11 |
| Average True Range (ATR) | 0.12 | 0.35 |
| MACD | -0.01 | 0.33 |
| Stochastic Oscillator | 1.96 | 10.03 |
Price Performance
Historical Comparison BTTC
ATRA
About BTTC Black Titan Corporation Ordinary Shares
Black Titan Corp is engaged in software implementation and training. It provides consulting services and Human Resource and Payroll solutions.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).